Latest Insider Transactions at Gilead Sciences, Inc. (GILD)
This section provides a real-time view of insider transactions for Gilead Sciences, Inc. (GILD). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of GILEAD SCIENCES, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of GILEAD SCIENCES, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 16
2024
|
Andrew D Dickinson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8,500
-6.03%
|
$773,500
$91.96 P/Share
|
|
Dec 13
2024
|
Sandra Patterson SVP, Controllership |
SELL
Payment of exercise price or tax liability
|
Direct |
157
-0.42%
|
$14,287
$91.86 P/Share
|
|
Dec 13
2024
|
Sandra Patterson SVP, Controllership |
BUY
Exercise of conversion of derivative security
|
Direct |
157
+0.42%
|
-
|
|
Dec 10
2024
|
Deborah H Telman EVP, Corporate Affairs & GC |
SELL
Payment of exercise price or tax liability
|
Direct |
306
-1.42%
|
$28,152
$92.34 P/Share
|
|
Dec 10
2024
|
Deborah H Telman EVP, Corporate Affairs & GC |
BUY
Exercise of conversion of derivative security
|
Direct |
639
+2.87%
|
-
|
|
Dec 10
2024
|
Sandra Patterson SVP, Controllership |
SELL
Payment of exercise price or tax liability
|
Direct |
408
-1.09%
|
$37,536
$92.34 P/Share
|
|
Dec 10
2024
|
Sandra Patterson SVP, Controllership |
BUY
Exercise of conversion of derivative security
|
Direct |
901
+2.35%
|
-
|
|
Dec 10
2024
|
Merdad Parsey Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,771
-2.09%
|
$162,932
$92.34 P/Share
|
|
Dec 10
2024
|
Merdad Parsey Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,820
+4.32%
|
-
|
|
Dec 10
2024
|
Daniel Patrick O'Day Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,762
-0.94%
|
$438,104
$92.34 P/Share
|
|
Dec 10
2024
|
Daniel Patrick O'Day Chairman & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,295
+1.99%
|
-
|
|
Dec 10
2024
|
Andrew D Dickinson Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,686
-1.18%
|
$155,112
$92.34 P/Share
|
|
Dec 10
2024
|
Andrew D Dickinson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,640
+2.49%
|
-
|
|
Dec 10
2024
|
Johanna Mercier Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,739
-2.26%
|
$159,988
$92.34 P/Share
|
|
Dec 10
2024
|
Johanna Mercier Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,752
+4.65%
|
-
|
|
Nov 29
2024
|
Andrew D Dickinson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
248,645
-39.54%
|
$22,875,340
$92.76 P/Share
|
|
Nov 29
2024
|
Andrew D Dickinson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
248,645
+13.47%
|
$17,156,505
$69.62 P/Share
|
|
Nov 27
2024
|
Merdad Parsey Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
164,211
-18.07%
|
$14,943,201
$91.88 P/Share
|
|
Nov 27
2024
|
Merdad Parsey Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
145,413
+26.6%
|
$8,870,193
$61.65 P/Share
|
|
Nov 26
2024
|
Jeffrey Bluestone Director |
SELL
Open market or private sale
|
Direct |
6,788
-43.21%
|
$617,708
$91.39 P/Share
|
|
Nov 26
2024
|
Jeffrey Bluestone Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+27.22%
|
$610,000
$61.26 P/Share
|
|
Nov 06
2024
|
Johanna Mercier Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-6.4%
|
$455,000
$91.28 P/Share
|
|
Nov 06
2024
|
Merdad Parsey Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
25,590
-10.61%
|
$2,328,690
$91.5 P/Share
|
|
Nov 06
2024
|
Merdad Parsey Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+16.65%
|
$1,425,000
$57.92 P/Share
|
|
Oct 25
2024
|
Deborah H Telman EVP, Corporate Affairs & GC |
SELL
Payment of exercise price or tax liability
|
Direct |
242
-1.14%
|
$21,538
$89.0 P/Share
|
|
Oct 25
2024
|
Deborah H Telman EVP, Corporate Affairs & GC |
BUY
Exercise of conversion of derivative security
|
Direct |
514
+2.36%
|
-
|
|
Oct 01
2024
|
Merdad Parsey Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,000
-1.96%
|
$166,000
$83.83 P/Share
|
|
Sep 12
2024
|
Merdad Parsey Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
21,246
-17.21%
|
$1,784,664
$84.5 P/Share
|
|
Sep 12
2024
|
Merdad Parsey Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+16.84%
|
$1,425,000
$57.92 P/Share
|
|
Sep 12
2024
|
Johanna Mercier Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
29,357
-14.74%
|
$2,436,631
$83.74 P/Share
|
|
Sep 10
2024
|
Deborah H Telman EVP, Corporate Affairs & GC |
SELL
Payment of exercise price or tax liability
|
Direct |
307
-1.46%
|
$24,867
$81.44 P/Share
|
|
Sep 10
2024
|
Deborah H Telman EVP, Corporate Affairs & GC |
BUY
Exercise of conversion of derivative security
|
Direct |
639
+2.95%
|
-
|
|
Sep 10
2024
|
Sandra Patterson SVP, Controllership |
SELL
Payment of exercise price or tax liability
|
Direct |
292
-0.79%
|
$23,652
$81.44 P/Share
|
|
Sep 10
2024
|
Sandra Patterson SVP, Controllership |
BUY
Exercise of conversion of derivative security
|
Direct |
901
+2.39%
|
-
|
|
Sep 10
2024
|
Daniel Patrick O'Day Chairman & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,749
-0.95%
|
$384,669
$81.44 P/Share
|
|
Sep 10
2024
|
Daniel Patrick O'Day Chairman & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,295
+2.01%
|
-
|
|
Sep 10
2024
|
Merdad Parsey Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,766
-1.76%
|
$143,046
$81.44 P/Share
|
|
Sep 10
2024
|
Merdad Parsey Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,821
+3.67%
|
-
|
|
Sep 10
2024
|
Andrew D Dickinson Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,682
-1.2%
|
$136,242
$81.44 P/Share
|
|
Sep 10
2024
|
Andrew D Dickinson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,641
+2.52%
|
-
|
|
Sep 10
2024
|
Johanna Mercier Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,734
-1.59%
|
$140,454
$81.44 P/Share
|
|
Sep 10
2024
|
Johanna Mercier Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,752
+3.32%
|
-
|
|
Aug 28
2024
|
Johanna Mercier Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
9,513
-8.27%
|
$742,014
$78.03 P/Share
|
|
Aug 13
2024
|
Johanna Mercier Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,490
-4.56%
|
$400,770
$73.98 P/Share
|
|
Aug 10
2024
|
Sandra Patterson SVP, Controllership |
SELL
Payment of exercise price or tax liability
|
Direct |
980
-2.65%
|
$71,540
$73.66 P/Share
|
|
Aug 10
2024
|
Sandra Patterson SVP, Controllership |
BUY
Exercise of conversion of derivative security
|
Direct |
3,678
+9.05%
|
-
|
|
Jul 25
2024
|
Deborah H Telman EVP, Corporate Affairs & GC |
BUY
Exercise of conversion of derivative security
|
Direct |
8,744
+16.42%
|
-
|
|
Jul 25
2024
|
Deborah H Telman EVP, Corporate Affairs & GC |
SELL
Payment of exercise price or tax liability
|
Direct |
2,917
-20.05%
|
$221,692
$76.51 P/Share
|
|
Jul 01
2024
|
Merdad Parsey Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,000
-2.03%
|
$136,000
$68.63 P/Share
|
|
Jun 10
2024
|
Andrew D Dickinson Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,662
-1.2%
|
$108,030
$65.25 P/Share
|